RE:RE:RE:RE:RE:RE:RE:RE:Technical420 reportI'm with you brother on being realistic....as I've had my hopes crushed by LABS over the last 6 months....but OTOH, I still stand by my assessment that they have achieved pretty much all what they said they would in terms of strategic plan....so on that basis I have optimism that once those activities start bearing fruit (IF), then we would be in far better shape. Again, this is coming from a guy who is a very large bag holder at the moment.....
Lemoyne wrote: Am being realistic here. The ramp up in backhalf 2020, I did feel ok about it, as there was COVID and glut/ transition year and whatever. But the intl news are just recent (summer/autumn), so they already were in COVID. The fact they give guidance for those intl revenues kicking in is of their own volition. If they don't realize the guidance they gave, it's on them. Now we don't know what this recent tech420 article refers to in terms of rampup but it sure doesn't sound good with recent track record.
We will see how it unfolds. I prefer taking a more pessimistic/ clearly more realistic pov considering recent track record and be happily surprised if they beat low expectations than being overly optimistic and getting my optimistic/unrealistic dreams crushed.
It's gonna take 2 years to get back to 2019 revenue levels/ end of 22- beg 2023,
IF they manage to keep up 30% growth QoQ. IMO, that's a big IF.
You look at LABS revenue/ transition and you've got to realize they are starting a new business. They have to deal with alot of issues they did not have to deal with when they were an extractor. ie: marketing, disitribution, production. In their videos, the machinery/by hand operations isn't fit for global scale mass production of CPG.
Righttothetop wrote: Lemoyne....you've certainly turned wet blanket dear boy....hopefully you're not too underwater....I know I am and am pissed, but geez....it's not like there hasn't been a global cataclysm that has hit the pause button on damn near everything except vaccine research and national debt spending....
Sure, did they say they were ramping up international stuff end of this year, beginning of next, you bet....did those predictions take a shyte kick because of covid stuff...probably....will this recover by next Q...who knows....but doubtful.
But the BoD wants someone different to take the reins and take this next step....that, more than anything else, will be the most telling on whether we continue to hold the bags or not....IMO
Lemoyne wrote: They twist the words to make it appear important. ie: I used information from tech420 articles (CGC being biggest client, posted during Q3) to try and make estimates. But CGC is biggest client for peanuts amount.
They keep pushing ramp up back. Remember: they said revenues would ramp up during backhalf of 2020, now its backhalf of 2021. Some of their press releases had intl sales in EU and LATAM in Q3/Q4 2020...
Competition wise, Althea (australia) announced they received registration for extract products in germany last month.
I doubt LABS manages to make Stada sales in feb 2021 as Pat said during Q3 cc.
There is a reason shorts kept piling on despite Q3 crash. I thought short float would diminish after Q3 drop but it actually went up...
So yeah, on top of Q4 being a coin toss, Q1 might not be a significant improvement.